GW2974

08/01/2010 - "Furthermore, the marked sensitivity of BK5.erbB2 mice to the inhibitory effects of GW2974 during tumor promotion suggest greater efficacy for this compound when erbB2 is overexpressed or amplified as an early event in the carcinogenic process."
01/01/2013 - "Similar results were observed in an intracranial GBM xenograft model, in which, although both doses of GW2974 slowed tumor growth, no improvement in survival was observed in mice treated with high-dose GW2974, presumably because of the augmentation of tumor invasion. "
01/01/2013 - "This offers a new perspective on the role of GW2974 in tumor progression, providing a potential strategy for GBM treatment based on precise prescription."
08/01/2010 - "GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice. "
07/01/2008 - "In a long-term post-initiation experiment (6-week topical DMBA followed by 18-week topical GW2974), GW2974 (4 mM and 8 mM) significantly inhibited the incidence, number and size of visible tumors. "

07/01/2007 - "[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis]."
07/01/2007 - "Topical application of GW2974 could significantly inhibit hamster buccal pouch carcinogenesis, which suggests that GW2974 may have a major impact in chemoprevention and treatment of oral cancer."
08/01/2010 - "In this study, to further examine the role of both erbB2 and EGFR in epithelial carcinogenesis, we examined the effect of a dual erbB2/EGFR tyrosine kinase inhibitor, GW2974, given in the diet on skin tumor promotion during two-stage carcinogenesis in wild-type and BK5.erbB2 mice. "
07/01/2008 - "In summary, our study indicated that dual inhibition of EGFR and ErbB2 tyrosine kinases by GW2974 was effective in preventing oral carcinogenesis in DMBA-induced hamster cheek pouch model. "
07/01/2007 - "To evaluate the inhibiting effects of GW2974, a tyrosine kinase inhibitors, on dimethyl-benzanthracene (DMBA)-induced Syrian golden hamster buccal pouch carcinogenesis. "

02/01/2007 - "A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines. "
08/01/2011 - "Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974). "

07/01/2010 - "We determined the effects of GW2974, a dual inhibitor of ErbB-1 and ErbB-2 tyrosine kinase activity, on growth, NSE, chromogranin A and osteopontin cytosol content in the androgen-independent prostate cancer cell line PC-3. "
07/01/2010 - "Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content."

07/01/2007 - "Topical application of GW2974 could significantly inhibit hamster buccal pouch carcinogenesis, which suggests that GW2974 may have a major impact in chemoprevention and treatment of oral cancer."